Approaching an age of reason with antiplatelet therapy

The Lancet

Volumn 371, Issue 9621, 2008, Pages 1315-1316

  Ajani, Andrew E ^a   Lefkovits, Jeffrey ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PRASUGREL;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CLINICAL TRIAL; CORONARY STENT; DRUG MECHANISM; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK REDUCTION; STROKE; THROMBOCYTE; THROMBOSIS; TREATMENT OUTCOME;

EID: 42149146101     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60573-5     Document Type: Note

References (12)

1. Wallentin L., Varenhorst C., James S., et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 29 (2008) 21-30
2. Payne C., Li Y., Small D., et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 50 (2007) 555-562
3. Wiviott S., Braunwald E., McCabe C., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
4. Wiviott S., Braunwald E., McCabe C., et al., for the TRITON-TIMI 38 Investigators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 371 (2008) 1353-1363
5. King III S., Smith Jr. S., Hirshfeld Jr. J., et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51 (2008) 172-209
6. Wiviott S., Trenk D., Frelinger A., et al., for the PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 116 (2007) 2923-2932
7. CURRENT/OASIS 7 study (Clopidogrel optimal loading dose Usage to Reduce Recurrent EveNTs) (March 18, 2008). http://www.clinicaltrials.gov/ct2/show/NCT00335452?term=CURRENT%2FOASIS+ 7&rank=1 (accessed April 10, 2008).
8. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 (2006) 1464-1476
9. Ndrepepa G., Berger P., Mehilli J., et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 51 (2008) 690-697
10. Serebruany V., and Atar D. Assessment of bleeding events in clinical trials-proposal of a new classification. Am J Cardiol 99 (2007) 288-290
11. Niitsu Y., Jakubowski J., Sugidachi A., and Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 31 (2005) 184-194
12. Yusuf S., Zhao F., Mehta S., et al., for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502